MediciNova Inc (MNOV)
1.91
+0.02
(+1.06%)
USD |
NASDAQ |
Sep 27, 16:00
1.95
+0.04
(+2.09%)
After-Hours: 20:00
MediciNova SG&A Expense (Annual): 5.242M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.242M |
| December 31, 2022 | 5.485M |
| December 31, 2021 | 5.715M |
| December 31, 2020 | 6.694M |
| December 31, 2019 | 7.952M |
| December 31, 2018 | 9.961M |
| December 31, 2017 | 8.803M |
| December 31, 2016 | 7.363M |
| December 31, 2015 | 5.805M |
| December 31, 2014 | 5.963M |
| December 31, 2013 | 6.658M |
| Date | Value |
|---|---|
| December 31, 2012 | 6.735M |
| December 31, 2011 | 8.324M |
| December 31, 2010 | 8.172M |
| December 31, 2009 | 10.37M |
| December 31, 2008 | 8.774M |
| December 31, 2007 | 11.37M |
| December 31, 2006 | 9.624M |
| December 31, 2005 | 7.479M |
| December 31, 2004 | 37.35M |
| December 31, 2003 | 1.538M |
| December 31, 2002 | 1.462M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
5.242M
Minimum
2023
7.952M
Maximum
2019
6.218M
Average
5.715M
Median
2021
SG&A Expense (Annual) Benchmarks
| BridgeBio Pharma Inc | 150.59M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 15.29M |
| iBio Inc | 11.67M |
| Theriva Biologics Inc | 7.12M |